Navigation Links
Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Date:7/2/2008

them for signs of anti-tumor activity. We look forward to sharing more data from this study as patient treatment and follow-up progress."

The primary objective of the multi-center Phase II clinical trial is to assess overall tumor response rate. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. All tumor responses in the trial are being evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Patients may continue to receive bavituximab as solo therapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in the Republic of Georgia according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) guidelines.

According to the RECIST criteria, patients are categorized as having "stable disease" ("SD") if they have less than a 20% increase to a 30% reduction in the sum of the target lesions, and they are categorized as having a "partial response" ("PR") if they experience greater than a 30% reduction in the sum of target lesions. In addition, to be assigned a status of SD or PR, patients cannot have the appearance of any new lesions.

According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 182,460 U.S. women will be diagnosed with breast cancer in 2008 and 40,480 women will die of the disease in the U.S. alone.

Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to h
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
2. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
3. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
5. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
6. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
7. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
8. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
9. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...., Dec. 1 Vanda Pharmace... in The Lancet , one of the world,s leading medic...el circadian regulator, experimental compound tasi...et al(1) is entitled "Melatonin agonist tasimelteo...e shift: two randomised controlled multicentre tri...
(Date:12/1/2008)...y shows the Prox1 gene is a two-way switch that, i...o be reprogrammed so that they lose their identity... , MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNewswi... Hospital have discovered that a certain different... that it requires the constant expression of a gen...
(Date:12/1/2008)... 1 GeoVax Labs, Inc.,(O...nology company developing,human vaccines for dise...) and,other infectious agents, announced today th...s will take place in twelve sites across North and...laboration with The National Institutes of,Health...
(Date:11/28/2008)... Nov. 28 Eli Lilly and C...tal New Drug Application (sNDA) from,the U.S. Foo...uloxetine HCl),for the management of chronic pain...first half of 2009, adding data from a recently co...pain of the knee. , The decision does not a...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Autism Learning Disabilities and ADHD Experts Convene at the Help Group Summit 26681 1Autism Learning Disabilities and ADHD Experts Convene at the Help Group Summit 26681 2Autism Learning Disabilities and ADHD Experts Convene at the Help Group Summit 26681 3New York City Skin Care Leader Juva Offering Latest Skin Resurfacing Innovation 26676 1New York City Skin Care Leader Juva Offering Latest Skin Resurfacing Innovation 26676 2Neurotechnology Releases SentiSight 2 0 SDK Universal Object Recognition Technology 5040 1Neurotechnology Releases SentiSight 2 0 SDK Universal Object Recognition Technology 5040 2Neurotechnology Releases SentiSight 2 0 SDK Universal Object Recognition Technology 5040 3UTSA UTHSCSA publish results on bio threat agent 7885 1UTSA UTHSCSA publish results on bio threat agent 7885 2
...Cancer and Other Human,Papillomavirus Related Dise...e Phase III Clinical Studies Which Included More T...e publishes the most comprehensive,and robust clin...YON, France, 10th May2007 – New clinical stu... of Gardasil® in the,prevention of cervical ca...
...007 - Antisense,Pharma, a German biopharmaceutical...ignant tumors, today announced, that data from the...a will be,presented at the 43rd Annual Meeting of ...which will be held in Chicago, Illinois,U.S.A, fr... dose-finding Phase,IIb-trial adult patients with ...
Other Medicine Technology:Gardasil Demonstrates Up to 100% Efficacy 2Gardasil Demonstrates Up to 100% Efficacy 3Gardasil Demonstrates Up to 100% Efficacy 4Gardasil Demonstrates Up to 100% Efficacy 5Gardasil Demonstrates Up to 100% Efficacy 6Gardasil Demonstrates Up to 100% Efficacy 72007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 22007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 3
(Date:12/1/2008)...lain and colleagues, at Memorial Sloan-Kettering C...ach to modulate the expression of genes for therap... anticancer therapy in mice. , Small, noncoding ... repressors of gene expression. In the study, the ...on of genes in immune cells known as T cells at di...
(Date:12/1/2008)...inn. - Disturbing evidence of higher mortality and...al valve prolapse and severe leakage may be relate...severity in women, according to findings of a Mayo...of Internal Medicine . , Mitral valve prolapse a...and often requires cardiac surgery, preferably val...
(Date:12/1/2008)...ec. 1 ViroPharma Incorpo...company submitted a supplemental,Biologics Licens...inistration,(FDA) for Cinryze(TM) C1 Inhibitor (h...ary angioedema (HAE). , The sBLA is based o...votal,Phase 3 acute treatment study of Cinryze an...
(Date:12/1/2008)...Dec. 1 Media entrepreneur, televis...investor and philanthropist John,Bendheim will be... their,annual "Road To A Cure" Gala, December 2, ...Rick Powell, Chairman of the Board of Governors, c...ron Kaplan and Fran Solomon. The "Road To,A Cure...
Breaking Medicine News(10 mins):Health News:Women with mitral valve prolapse are treated less aggressively than men and may be at high risk 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:Cedars-Sinai Board of Governors to Honor Ryan Seacrest & John Bendheim at Annual 'Road To A Cure' Gala 2
...ke adults, children are likely to suffer hearing l...sic, power generators, drilling machines and firec...urvery says that 5 million children have noise-ind...f the loss is only in one ear, the child's overall...
...art disease, in any form is unquestionably one of ... planet. The scientists of the globe are working o...is better than cure. As a result of their hard wor...ify and stop the progression when the disease is y...
...abetes mellitus type I, is due to autoimmune destr...insulin. Result of this the body no longer produce...gar levels. Individuals with this type I Diabetes ...heart disease even at their teens. The team of res...
...DS in developing countries is a threeat to the glo...he United Nations General Assembly Special Session...e cost of anti retroviral therapy that would cater...s. Dr. Anne-Valerie Kaninda, medical advisor for D...
Other Medicine News:
Knot pusher/suture retriever
The RC Retractor comes with several blade sizes to allow for superficial or deep muscle retraction. The RC Retractor permits retraction in three different directions: medial, lateral and inferior.
Shoulder rasp
12" suture passer
Medicine Products: